

PRESS RELEASE



GSK Renews its Contribution to CQDM to Sustain Innovation in Quebec and Canada

The renewed \$500,000 commitment will continue to fund disruptive research and technology projects that could exponentially improve new drug discovery

Laval, QC, June 20, 2017 – Five years after having joined CQDM through its Explore Program, GlaxoSmithKline Inc. (GSK) has reaffirmed its support for innovative research and technologies by contributing an additional \$500,000 to CQDM over five years. By the end of 2022, GSK will have committed a total \$1 million to CQDM, helping to fund avant-garde approaches to resolve some of the most pressing issues in biopharmaceutical research and development (R&D).

With this consolidated partnership, both organizations intend continuing their efforts to invest in the Quebec and Canada life sciences sector with a unique blend of academic and industrial know-how. The collaboration enhances CQDM's capacity to support pre-competitive, pre-clinical platforms which accelerate the drug discovery and development process, allowing the best healthcare solutions to reach the market sooner and to benefit patients, practitioners and caregivers.

“We are delighted to continue our partnership with CQDM which offers an attractive platform to invest in disruptive science while sharing the costs and rewards. Gone are the days when in-house R&D only would suffice to find transformational solutions to complex healthcare challenges,” said Paul Lirette, President, Canada Pharmaceuticals, GSK. “As a global leader in healthcare, innovation underpins everything we do and this is why bolstering the life sciences ecosystem in Quebec and Canada is such an important endeavor for GSK.”

“We are pleased that GSK is renewing its faith in, and support of, our organization and our unique business model. By working with CQDM, GSK is one of the partners helping to generate strong financial leverage to de-risk particularly innovative projects which could not be developed otherwise. Investments such as the one announced today serve to confirm that we properly manage the funds entrusted to us; these funds are used to feed the innovation pipeline which allows our pharmaceutical partners to have access to results which are used to accelerate drug discovery,” said Diane Gosselin, President & CEO of CQDM.

Since inception of the Explore Program, GSK and CQDM together with other industry members have identified and supported 21 cutting-edge research and development projects, totalling \$6.6M in funding and providing high-quality opportunities for some 50 investigators in 22 academic or private institutions. These projects span the most important therapeutics areas for the biopharmaceutical industry such as Neurosciences; Infection and immunity; Oncology; and Cardiovascular diseases, and address the most pressing unmet needs of biopharmaceutical research.

About GlaxoSmithKline Inc. (GSK)

One of the world's leading research-based pharmaceutical and healthcare companies – GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit www.ca.gsk.com.

About CQDM

CQDM is a pharma-based consortium active in early research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM's business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. CQDM receives financial support from Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Janssen, Novartis Pharma Canada, Sanofi Canada, as well as from Quebec's Ministry of Economy, Science and Innovation (MESI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information: www.cqdm.org.

-30-

GSK Media Enquiries:

Emmanuel Fritsch
1-450-680-4812
(Laval, QC)

CQDM Media Enquiries:

Catherine Lamontagne
Communications Strategist and Coordinator
(450) 578-0878 | catherine@orokom.com